Tectonic Therapeutic Appoints Daniel Lochner as CFO

WATERTOWN, Mass.–(BUSINESS WIRE)–Tectonic Therapeutic, Inc., a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic.

“Dan is an experienced public-company CFO who will add significant financial expertise to our team,” said Alise Reicin, MD, President and Chief Executive Officer of Tectonic. “With his extensive background in the healthcare and biopharmaceutical industries, Dan is an important addition to the Tectonic team, and we are thrilled to welcome him as Chief Financial Officer.”

Dan brings with him a wealth of knowledge in corporate finance, business strategy and operations, in addition to nearly 15 years of healthcare equity investing experience. Prior to joining Tectonic, he served as Chief Business Officer and Chief Financial Officer of Viatris’ Eye Care Division following Viatris’ acquisition of Oyster Point Pharma, where he had previously served as Chief Financial Officer and Chief Business Officer. At Oyster Point Pharma, he drove business strategy and operational execution while working closely with the executive team and board of directors and played a key role in the company’s acquisition. Previously, Dan was a Managing Director and Equity Portfolio Manager at Goldman Sachs where he held positions of increasing responsibility in equity investing and fund management. During his time at Goldman Sachs, he invested in biotechnology, pharmaceuticals, medical devices and healthcare services companies. Dan received his MBA from Columbia University and his BA in Economics from the University of Richmond.

“It is an honor to join the Tectonic team at the beginning of this new chapter. The company is operating at the forefront of scientific innovation with a mission to unlock the therapeutic utility of GPCRs for which biologics offer advantages over small molecule pharmacology,” said Mr. Lochner. “I’m honored to be joining the Tectonic team as it advances a pipeline of novel GPCR targeted biologic therapies.”

Christian Cortis, Ph.D., the current Chief Operating Officer and Chief Financial Officer will be leaving the company to pursue external opportunities. He will remain with Tectonic through early July to assist in the transition, and afterwards will serve as a strategic advisor to the company. “I cannot thank Chris enough for the integral role he played from day one with Tectonic, from the company’s launch to the merger with AVROBIO which is expected to close later this month. As our first employee, his guidance and strategic and operational know-how have been instrumental as we worked to become a clinical stage company,” added Dr. Reicin.

About Tectonic Therapeutic

Tectonic Therapeutic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting GPCRs to develop novel therapies for patients inadequately served by current treatments. With its proprietary GEODe™ platform, Tectonic aims to unlock the therapeutic utility of some of the most difficult receptors in the class, where small molecule pharmacology may be intractable. In January 2024, Tectonic entered into a definitive agreement to merge with AVROBIO, Inc. (Nasdaq: AVRO). Tectonic is headquartered in Watertown, Massachusetts. Learn more at www.tectonictx.com and follow us @TectonicTx.